GSA Capital Partners LLP boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 475.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,308 shares of the biopharmaceutical company's stock after buying an additional 30,830 shares during the period. GSA Capital Partners LLP's holdings in Xenon Pharmaceuticals were worth $1,469,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the business. TimesSquare Capital Management LLC boosted its stake in Xenon Pharmaceuticals by 3.2% during the third quarter. TimesSquare Capital Management LLC now owns 778,293 shares of the biopharmaceutical company's stock worth $30,641,000 after buying an additional 23,800 shares in the last quarter. Assetmark Inc. boosted its stake in shares of Xenon Pharmaceuticals by 7.9% in the 3rd quarter. Assetmark Inc. now owns 19,670 shares of the biopharmaceutical company's stock valued at $774,000 after purchasing an additional 1,435 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of Xenon Pharmaceuticals by 99.3% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 48,063 shares of the biopharmaceutical company's stock valued at $1,892,000 after purchasing an additional 23,947 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Xenon Pharmaceuticals by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,572 shares of the biopharmaceutical company's stock valued at $574,000 after purchasing an additional 5,704 shares in the last quarter. Finally, abrdn plc boosted its stake in shares of Xenon Pharmaceuticals by 16.9% in the 3rd quarter. abrdn plc now owns 248,311 shares of the biopharmaceutical company's stock valued at $9,776,000 after purchasing an additional 35,809 shares in the last quarter. Institutional investors and hedge funds own 95.45% of the company's stock.
Xenon Pharmaceuticals Stock Performance
Xenon Pharmaceuticals stock traded up $0.11 during trading hours on Thursday, reaching $42.08. 82,411 shares of the company's stock traded hands, compared to its average volume of 384,739. The firm has a market capitalization of $3.19 billion, a price-to-earnings ratio of -14.91 and a beta of 1.25. The firm's 50 day moving average is $41.14 and its 200-day moving average is $40.35. Xenon Pharmaceuticals Inc. has a fifty-two week low of $28.10 and a fifty-two week high of $50.99.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($0.82) by $0.01. During the same quarter last year, the company earned ($0.73) earnings per share. Analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on XENE. Needham & Company LLC restated a "buy" rating and issued a $60.00 target price on shares of Xenon Pharmaceuticals in a research note on Wednesday. HC Wainwright reiterated a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday. Wedbush reduced their price target on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an "outperform" rating on the stock in a research report on Friday, August 9th. Raymond James reiterated an "outperform" rating and set a $50.00 price target on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 price target on shares of Xenon Pharmaceuticals in a research report on Friday, August 9th. Eleven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $57.45.
Get Our Latest Analysis on Xenon Pharmaceuticals
Xenon Pharmaceuticals Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
